Our latest deal : Domain Therapeutics raises $42M series A
Achievement of the study’s primary endpoint, confirming glenzocimab’s very favorable safety profile Reduction in the number of intracerebral hemorrhages and
Bouriser.com – Depuis vendredi, l’offre de titres Acticor est lancée dans le cadre de son augmentation de capital d’environ 20
Paris, July 22, 2021 – Acticor Biotech, a clinical stage biotechnology company developing an innovative drug for the acute phase
Paris, July 1st, 2021 – Acticor Biotech, a clinical stage biotechnology company involved in the acute phase of thrombotic diseases,
Towards a new standard for device indication: Implantation for temporary or permanent use • Easy removal with a beating heart
by Jean-Alexandre Kaminisky, 2021-03-18 Karista invests in MyPL increasing its financing to €1.8m & accelerating its development Paris – France, March
Achievement of the study’s primary endpoint, confirming glenzocimab’s very favorable safety profile Reduction in the number of intracerebral hemorrhages and
Introductions : Acticor, 20 ME à lever
Bouriser.com – Depuis vendredi, l’offre de titres Acticor est lancée dans le cadre de son augmentation de capital d’environ 20
Paris, July 22, 2021 – Acticor Biotech, a clinical stage biotechnology company developing an innovative drug for the acute phase
Latest Insights
Paris, January 7th, 2020 – PKvitality, a French company specialized in bio wearables, has signed an agreement with Beurer GmBH,
This press release may not be published, forwarded or distributed, directly or indirectly in the United States of America, Canada,
Paris, France, July 10, 2017 – The European Investment Bank (EIB) and Cellnovo Group (“Cellnovo” or the “Company” CLNV:EN Paris), a
Paris, October 16, 2018 – Acticor Biotech, a clinical stage biotechnology company involved in the acute phase of thrombotic diseases, including
– SoniVie Acquires New Intellectual Property and Other Assets from Cardiosonic Moving TIVUS into New Therapeutic Areas Beyond Pulmonary Hypertension